Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
This Office Action is in response to Applicant’s Arguments and Amendment filed, 08/24/2026, wherein the Amendment amended claims 1 and 4-10.
Claims 1-24 are pending and examined on the merits herein.
Priority
This application claims the following priority:
PNG
media_image1.png
138
652
media_image1.png
Greyscale
REJECTIONS WITHDRAWN
The status for each rejection and/or objection in the previous Office Action is set out below.
35 U.S.C. § 112(b)
Regarding the rejection of claims 15-22 over the term “baseline,” Applicant persuasively argues that the Specification clearly identifies “baseline” as a measurement taken prior to onset of the instantly claimed treatment. Applicant specifically points to paragraphs [0055]-[0056], [0060]-[0064], which specifically references post-baseline visits (this appears to be a reference to the PGPub of the Instant Application, 2024/0075040). See also pgs. 11-14 of the Specification. On pgs. 55-56, 59, 61, Specification, in reference to patients beginning therapy, a “baseline visit” is referenced. On pg. 44, Specification, “the baseline visit” is referenced.
See also pgs. 7-9, Remarks.
Thus, it is clear that “baseline,” as recited in the claims, is referencing a baseline measure of individual patients prior to beginning the instant methods of treatment.
Regarding the rejection over the phrase “achieves an improvement,” in claim 16, Applicant persuasively argues that a person of ordinary skill in the art would readily understand that improvement with respect to an Itch Numeric Rating Scale (NRS) is demonstrated by a reducing in the score relative to a baseline values. See pg. 10, Remarks.
35 U.S.C. § 103
Applicant’s amendment to claim 1 that limits ruxolitinib as the only active agent in the method is sufficient to overcome the rejection since Arkin’s composition requires both an EGFR inhibitor and a JAK inhibitor, i.e., two active agents.
Statutory Double Patenting
Applicant’s amendment to claim 1 that limits ruxolitinib as the only active agent is sufficient to overcome this rejection since neither copending Application Nos. 19/544,334 nor 19/298,956 recite ruxolitinib as the only active agent.
REJECTIONS-MAINTAINED, MODIFIED, NEW
Applicant’s amendments to the claims that adds the limitation “wherein the ruxolitinib. . .is the only active agent,” to independent claim 1, have resulted in the below new and modified rejections.
Specification
(Maintained) The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code; references to websites should be limited to the top-level domain name without any prefix such as http:// or other browser-executable code. See MPEP § 608.01.
See, for example, pg. 44.
Claim Rejections - 35 USC § 112(d)
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
(New) Claim 24 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Claim 24 depends from claim 1, wherein claim 1 recites “wherein ruxolitinib. . .is the only active agent.” However, claim 24 recites “wherein the ruxolitinib. . .is administered in combination with a further therapeutic agent,” thereby broadening the scope of claim 1, from which claim 24 depends. As such, claim 24 does not further limit claim 1, from which it depends.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
(Modified) Claims 1-13 and 15-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-, 30-31, 49, 55-56, 59, and 62 of copending Application No. 18/670394 (claim set dated 05/21/2024, reference application).
Note: In reference to the footnote on pg. 18, Remarks, it is pointed out that this Double Patenting Rejection is correctly applied over Application No. 18/670394. This Application number was clearly identified in the previous Office Action.
Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claim 1, ‘394 claims a method of treating prurigo nodularis by administering a composition comprising ruxolitinib (claims 1, 46, 49, 61, 62), wherein ruxolitinib is claimed as the only active agent.
Regarding claims 3-4, ‘394 claims the composition as topically applied to a body surface area affected by the disease (claim 1).
Regarding claim 2, ‘394 claims ruxolitinib phosphate (claims 30-31).
Regarding claims 5-10, ‘394 claims ruxolitinib as comprising 0.5-3% by weight on a free base basis (claims 34, 41).
In the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. See MPEP 2144.05.
Regarding claims 11-13, though ‘394 does not teach how frequently or for how long the formulation is administered, an ordinary skilled artisan would have been motivated to select administration once or twice per day for at least 12 weeks, of the formulation of ‘394, to predicably arrive at a dosing regimen that is effective to treat the prurigo nodularis.
"[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." MPEP 2144.05(II)
Though ‘394 does not teach the functional limitations of instant claims 15-22, it is reasonable to assume that the combination of these references which teaches administering ruxolitinib, in amounts effective to treat prurigo nodularis, to the same patient population (patients with prurigo nodularis), as that taught by the instant specification and claims, would have the same properties. Thus, while the prior art does not explicitly teach these properties, burden is on Applicant to show that the prior art does not have these properties. See MPEP 2112.02.
Applicants are reminded that the office does not have the facilities and resources to provide the factual evidence needed in order to establish that the product of the prior art does not possess the same material, structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is on the applicant to prove that the claimed product is different from those taught by the prior art and to establish patentable differences. See In re Best 562F.2d 1252, 195 USPQ 430 (CCPA 1977) and Ex parte Gray 10 USPQ 2d 1922 (PTO Bd. Pat. App. & Int. 1989).
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
(New) Claims 1-24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-24 of copending Application No. 19/544,334 (claim set dated 02/19/2026, (reference application).
Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claim 1, ‘334 claims a method for treating prurigo nodularis in a subject comprising administering a therapeutically effective amount of ruxolitinib or a pharmaceutically acceptable salt thereof, wherein ruxolitinib is claimed as the only active agent (claim 1).
Claims 2-24 of ‘334 corresponds to instant claim 2-24.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
(New) Claims 1-24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-24 of copending Application No. 19/298,956 (claim set dated 08/13/2025, reference application).
Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claim 1, ‘956 claims a method for treating prurigo nodularis in a subject comprising administering a therapeutically effective amount of ruxolitinib or a pharmaceutically acceptable salt thereof, wherein ruxolitinib is claimed as the only active agent (claim 1).
Claims 2-24 of ‘956 corresponds to instant claim 2-24.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
(New) Claims 1-23 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-2, 14-17, 22-23, and 25-44 of copending Application No. 18/973,200 (claim set dated 07/23/2025, reference application).
Although the claims at issue are not identical, they are not patentably distinct from each other.
Regarding claims 1, 3-7, 10-11, ‘200 claims a method of treating prurigo nodularis in a human patient comprising topically administering to an affected skin area of the patient, ruxolitinib or a pharmaceutically acceptable salt thereof, as a topical formulation twice per day, wherein the ruxolitinib is the only active agent and comprises about 1.5%w/w of the ruxolitinib (claims 1, 29, 35).
Regarding claim 2, ‘200 claims ruxolitinib phosphate (claim 2).
Claims 2 and 13-28 of ‘200 correspond to instant claims 2 and 13-23. See also claims 29-44.
Regarding claims 8-9 and 12, an ordinary skilled artisan would have been motivated to modify the percent weight of ruxolitinib and the times per day it is administered to predictably arrive at a method of treatment that is optimized to treat prurigo nodularis with minimal adverse effect. Moreover, "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." MPEP 2144.05(II)
The optimization of known amounts for known active agents is considered well within the competence level of an artisan of ordinary skill in the pharmaceutical sciences; it has been held that the selection of optimal parameters, such as amounts of active agents, to achieve a beneficial effect, is within the skill in the art of an ordinary artisan. See In re Boesch, 205 USPT 215 (CCPA 1980) and MPEP 2144.05.
This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented.
Free of the Prior Art
Claims 1-24 are free of the prior art.
The closest prior art is Molloy (“Successful treatment of recalcitrant nodular prurigo with tofacitinib,” published 10/07/2023, PTO-892 of 05/12/2026) which teaches the treatment of nodular prurigo with tofacitinib administered orally (title), wherein tofacitinib is taught as a JAK inhibitor (pg. 919, Col. 1, 1st full paragraph).
The reference does not teach ruxolitinib, which is a distinct feature of the instantly claimed method.
Clark, NPL No. 45 of the 04/11/2025 IDS, teaches the enzyme IC50 values for tofacitinib and ruxolitinib on JAK1, JAK2, JAK3, and TyK2 (pg. 5029). The table clearly shows that a) ruxolitinib is about twice as potent as tofacitinib for JAK1, b) ruxolitinib is about eight times more potent than tofacitinib for JAK2, c) tofacitinib is at least eight times more potent than tofacitinib than ruxolitinib for JAK3, and d) ruxolitinib is sixteen times more potent than tofacitinib for TYK2.
In summary, ruxolitinib is selective for JAK1, JAK2 and TYK2, while tofacitinib is selective for JAK2.
Clark on pg. 5031, Col. 2, further teaches “As indicated in Table 1, unlike tofacitinib, ruxolitinib and baricitinib exhibit specificity for JAK1 and JAK2 over JAK3 in kinase assays.”
As such, Clark clearly teaches that tofacitinib and ruxolitinib are not equivalent, and that tofacitinib is a JAK 1/3 inhibitor while ruxolitinib is a JAK 1/2 inhibitor. Thus, there would be no reasonable expectation of success that substituting tofacitinib, a JAK 1/3 inhibitor, with ruxolitinib, a JAK1/2 inhibitor, would treat prurigo nodularis (PN).
Additionally, Molloy teaches the treatment of a single patient with prurigo nodularis (PN) with tofacitinib. While the patient’s prurigo nodularis (PN) is treated, Molloy further reports, on pg. 919, that there is also a case report of treatment failure of PN with tofacitinib, and that it is unclear whether that was due to adverse events or inefficacy.
As such, since it is not predictable that tofacitinib will treat PN, it is further not predictable that ruxolitinib will treat PN; there is no reasonable expectation of success.
Conclusion
No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAUREN WELLS whose telephone number is (571)272-7316. The examiner can normally be reached M-F 7:00-4:30.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James (Jim) Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LAUREN WELLS/Primary Examiner, Art Unit 1622